



# The Barry-Wainberg DART Achievement Award





# David Barry, MD

1943 - 2002

- BA in French Literature (1965) and MD (1969) from Yale University
- Junior year abroad at The Sorbonne, Paris
- Co-inventor of AZT
- Directed clinical development of acyclovir
- 5 years at FDA
- 18 years with Wellcome plc and subsidiaries
- President of The Wellcome Research Labs
- Chairman of the Inter-Company Collaboration on AIDS Drug Development
- Founder of Triangle Pharmaceuticals







# Mark Wainberg, PhD

1945-2017

1966 BS McGill University  
1972 PhD Columbia University

- Director of the McGill University AIDS Center
- Director of Research at the Jewish General Hospital's Lady Davis Institute for Medical Research
- Professor of Microbiology and Immunology at McGill University
- First scientist in Canada to grow HIV
- First identified 3TC in collaboration with BioChem Pharma Inc. (1989)
- 1998-2000 IAS President
- 2000 Officer of the Order of Canada
- 2005 Officier L'Ordre National Du Quebec
- 2008 Knight of the Legion of Honor
- 2016 Inducted into the Canadian Medical Hall of Fame
- >500 HIV papers
- ART efficacy, resistance, advocacy, cure



*Dr. Wainberg was the recipient of HIV DART Gertrude Elion distinguished lecture award*



# Previous Awardees



- 2002 Robert Siliciano, *Johns Hopkins University School of Medicine, USA*
- 2004 Daria Hazuda, *Merck Research Laboratories, USA*
- 2006 Hiroaki Mitsuya, *Kumamoto University School of Medicine, Japan*
- 2008 Brendan Larder, *RDI, UK*
- 2010 Dale Kempf, *Abbott Laboratories, USA*
- 2012 Samuel Broder, *National Cancer Institute, USA*
- 2014 Julio Montaner, *BC Centre for Excellence in HIV/AIDS, Canada*
- 2016 Ronald C. Desrosiers, *University of Miami, USA*
- 2018 Bonaventura Clotet, MD, PhD, IrsiCaixa, Spain**



# Dr. Bonaventura Clotet, MD, PhD



- 1976 MD at the Universitat Autònoma de Barcelona
- 1981 PhD for his investigations on surrogate markers for connective tissue diseases
  
- 1986-present Associated professor of Medicine at the Universitat Autònoma de Barcelona (UAB)
- 1987-2015 Head of the HIV Unit of the Hospital Germans
- 1992-present President of the “Lluita contra la SIDA” Foundation
- 1994-2010 Member of the steering committee of EuroSIDA (multicenter group for the study of AIDS in Europe)
- 1995-present Director of the Retrovirology Laboratory “IrsiCaixa” Foundation
- 1997-2006 Co-director of AIDS cyberjournal (ACJ)
- 2001-2011 Member of the Drug Resistance Mutations Group (IAS-USA)
- 2002-2010 Governing Council of the IAS
- 2006-present Co-director of the HIVACAT project (AIDS vaccine) in Catalonia, Spain.
- 2009-2015 Scientific Advisory Board Member of Fundació Príncep de Girona
- 2010 Lifetime scientific career award by the Catalan Institute of Health









# Dr. Bonaventura Clotet, MD, PhD



Dr. Clotet's team: 150 people working at the clinics and at the lab focusing on:

HIV, immune system abnormalities and related infectious diseases, cancer, papiloma virus, metagenomics, hepatitis and NASH, and aging.

Dr. Clotet has created 2 spin-offs from IrsiCaixa:

1. **AELIX Therapeutics** (December 2015): Therapeutic vaccine for HIV infected patients. With the involvement of Johnson & Johnson, Ysios & Caixa Capital-Risc. Total amount: 11.5 M€.
2. **AlbaJuna Therapeutics** (January 2016): Immunoglobulin for curing & preventing HIV. With the involvement of Grifols SA (GROWL). Total amount: 11 M€.



➤ **800 papers** in international journals





# The Barry-Wainberg DART Achievement Award Lecture: “How AIDS research has evolved to many other fields”



**Bonaventura Clotet, MD, PhD**

Fundació Lluita contra la Sida and Fundació Irsicaixa,  
Universitat Autònoma de Barcelona, Spain